//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Registration

Online Registration is Open!
Register by Friday, May 1 to Save Up to $200!

Download Brochure

Add to Outlook Calendar

Find Another IBC Event

Bioconjugates: From Targets to Therapeutics

CSS

Transitioning Innovation into Viable Therapeutic Candidates

May 18-20, 2015 | Parc 55 Hilton | San Francisco, CA

Alt language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese

SurveyMonkey

We Want Your Opinion! Help us better understand where the biggest opportunities are to advance cancer therapeutics. » Please share your insights

Event Overview

Event Overview

Bringing Together Protein Engineers with Medicinal Chemists
in an Interdisciplinary Forum to Foster Innovation

This is the first and only conference to focus on bioconjugation techniques from a holistic standpoint. Going beyond just ADCs, to look at the latest research and innovations across all topics within bioconjugates including ADCs, bispecific conjugations, nanoparticle conjugations and more.

brochure cover

Complete Brochure Now Available
» Download Today!

"It was a pleasure presenting at the Bioconjugates conference in June 2014. The presentations and discussion were very stimulating and there was excellent new information." - Philip Howard, Ph.D., Chief Scientific Officer, Spirogen, United Kingdom

By Attending You Will:

  • Gain insights on novel payloads, new linkers and alternative binding modalities, and updates on the latest in ADC discovery and development
  • Hear Seattle Genetics and Genentech present their strategies for overcoming CMC and regulatory challenges
  • Learn from advances beyond ADCs, including bispecific conjugations, nanoparticle conjugations and more

"Great variety of bioconjugation modalities. I'm sure this sort of crosstalk will create new innovations." - Roger Pak, Pfizer

Keynote Presentations

Peter Senter, Ph.D.

Potent Antibody Drug Conjugates for Cancer Therapy
Peter Senter, Ph.D.
Vice President, Chemistry
Seattle Genetics

Paul J. Carter, Ph.D.

Bispecific Antibodies - Are We There Yet?
Paul J. Carter, Ph.D.
Staff Scientist and Senior Director, Antibody Engineering
Genentech, Inc.

Andreas Plückthun, Ph.D.

New Engineering and Application Perspectives of Scaffold Proteins
Andreas Plückthun, Ph.D.
Director, Department of Biochemistry
University of Zurich, Switzerland

Patrick Baeuerle

Development of Bite® Antibody Construct Blinatumomab - The First FDA-Approved Bispecific Antibody
Patrick Baeuerle
Vice President, Research; General Manager
Amgen Research GmbH, Germany

James A. Wells, Ph.D.

Engineered Proteins for Signaling
Jim Wells, Ph.D.
Professor and Chair, Pharmaceutical Chemistry
UCSF

Mark S. Dennis

Receptor-Mediated Delivery of Bispecific Antibodies into the Primate Brain: Challenges and Safety Findings
Mark Dennis, Ph.D.
Principal Scientist, Antibody Engineering
Genentech, Inc.

"A great conference with all the experienced scientists involved in ADC therapeutics - 'one-and-only shop for ADCs' - great location too." - Ananda Senevir, Agensys

Now Accepting Speaker Submissions

Submit Now
Deadline to submit is December 17

Antibody Engineering & Therapeutics China